Print Page  |  Close Window

Investor Center

Recent Press Releases

Neuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury

04/12/17 - Investigating New Patient Cohort with Cervical Injury GERMANTOWN, Md., April 12, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based o... More

Neuralstem Reports Year End 2016 Fiscal Results and Business Update

03/23/17 - Expects to Report NSI-189 Phase 2 major depressive disorder study results in Q3 ahead of schedule GERMANTOWN, Md., March 23, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the dev... More

Neuralstem to Present at Oppenheimer 27th Annual Healthcare Conference on March 21

03/17/17 - GERMANTOWN, Md., March 17, 2017 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, announces that Rich ... More

Upcoming Events


There are currently no events scheduled.